Nebulized MSC Exosomes for Respiratory and Pulmonary Research
Inhaled delivery is one of the few administration routes for mesenchymal stem cell (MSC)-derived exosomes with published human clinical data behind it. Because exosomes are nanoscale vesicles, they can be aerosolized and delivered directly to lung tissue rather than travelling through systemic circulation. BioRegenEx supplies MSC-derived exosomes to licensed physicians and clinics across the United States as characterized, research-use-only material.
Why the inhaled route draws research interest
The lung presents a delivery problem that most biologics struggle with: getting an intact therapeutic agent to alveolar tissue at a useful concentration. Nebulization turns a liquid into an aerosol fine enough to reach the lower airway directly. For a nanoscale vesicle this is attractive in principle, and it is the reason the earliest human work on exosome administration outside of injection was done by inhalation.
What the research explores
Published research examines signaling related to alveolar epithelial repair, pulmonary inflammation, and mitochondrial transfer in acute lung injury models. Two clinical investigations of nebulized umbilical cord MSC-derived vesicles have now been published. These are research findings only and do not establish safety or efficacy for any indication.
Key Published Research
Human clinical evidence listed first, then preclinical. Every entry links to its PubMed record.
- Clinical investigation on nebulized human umbilical cord MSC-derived extracellular vesicles. Signal Transduct Target Ther, 2025. HUMAN clinical investigation. (PubMed)
- Nebulization therapy with umbilical cord mesenchymal stem cell-derived exosomes. Stem Cell Rev Rep, 2022. HUMAN clinical study. (PubMed)
- AdMSC-derived exosomes alleviate acute lung injury via transferring mitochondria. Theranostics, 2022. Preclinical. (PubMed)
- Extracellular vesicles in the pathogenesis and treatment of acute lung injury. Mil Med Res, 2022. Review. (PubMed)
- Extracellular vesicles and the lung: from disease pathogenesis to biomarkers. Physiol Rev, 2025. Review. (PubMed)
- Idiopathic pulmonary fibrosis microenvironment: novel mechanisms and research directions. Int Immunopharmacol, 2025. Review. (PubMed)
Browse the full Exosome Research Library
The material BioRegenEx supplies
Our sterile saline serum containing 100 billion exosomes can be nebulized. The same preparation is also used as eye drops. It is supplied as characterized, research-use-only material with per-lot documentation.
Sourcing considerations
For research use, look for characterized lots (particle size and concentration), sterility and endotoxin screening, cold-chain handling, and clear research-use-only labeling. Aerosolized and ophthalmic use place particular weight on sterility documentation and on the carrier the vesicles are suspended in.
Frequently Asked Questions
Are nebulized MSC exosomes an approved respiratory treatment? No. They are not FDA-approved to treat any respiratory condition and are supplied for research use only.
Is there human data? Two clinical investigations of nebulized umbilical cord MSC-derived vesicles have been published, both linked above. This is early human research, not evidence of efficacy.
BioRegenEx supplies MSC-derived exosomes for research use only (RUO). They are not intended to diagnose, treat, cure, or prevent any disease. This content is educational and is not medical advice.